Send us Feedback

Advanced Medical Optics (EYE)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
OPERATING METRICS
REVENUE SOURCES
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

EYE » Topics » Notes to the Unaudited Pro Forma Condensed Combined Statement of Operations

This excerpt taken from the EYE 8-K filed Jun 6, 2006.

Notes to the Unaudited Pro Forma Condensed Combined Statement of Operations

 

(1) Reflects amortization of the fair value of the intangible assets acquired in the VISX merger.

 

(2) Reflects the adjustment to decrease research and development expense by the $488.5 million in-process research and development charge resulting from the application of purchase accounting to the VISX merger.

 

(3) Reflects an increase of interest expense and amortization of debt issuance cost related to additional borrowings incurred to fund the cash portion of the VISX acquisition and related costs and amortization of deferred financing costs ($0.1 million per annum). The pro forma interest expense arising from the additional borrowings has been computed based upon $200.0 million aggregate borrowings and an average interest rate of 5.63% assumed to be borrowed at the beginning of the year and repaid upon close of the acquisition. The unaudited pro forma information also reflects a $2.0 million decrease of interest expense related to the amortization and write-off of debt issuance costs.

 

(4) Reflects the pro forma tax effect of the above adjustments to yield an estimated combined effective tax rate of 34% for the year ended December 31, 2005. The effective tax rate of 34% includes the impact of a $5.7 million tax benefit from the repatriation of foreign earnings. In addition, no tax benefits were recognized for the impact of $11.0 million of pre-tax acquisition charges incurred by VISX and a $8.6 million pre-tax charge associated with the termination of a distribution agreement in India that we had with our former parent.

 

(5) The unaudited pro forma combined information reflects the issuance of 27.8 million shares of our common stock to VISX shareholders less the 16.6 million weighted average shares related to the VISX merger included in AMO historical weighted average shares outstanding.

 

(6) The unaudited pro forma combined information reflects the issuance of 27.8 million shares of our common stock to VISX shareholders less the 16.6 million weighted average shares related to the VISX merger included in AMO historical weighted average shares outstanding, and the net aggregate dilutive effect of approximately 3.3 million AMO stock options and awards and VISX stock options exchanged for AMO options.

 

(7) Unaudited condensed consolidated results of operations of VISX for the three months ended March 31, 2005

 

(8) Unaudited condensed consolidated results of operations of VISX for the period April 1, 2005 through May 27, 2005 (effective date of the merger).
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki